X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with FDC LTD. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA FDC LTD. NATCO PHARMA/
FDC LTD.
 
P/E (TTM) x 30.5 24.2 126.1% View Chart
P/BV x 23.1 5.0 458.1% View Chart
Dividend Yield % 0.5 0.9 52.8%  

Financials

 NATCO PHARMA   FDC LTD.
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
FDC LTD.
Mar-14
NATCO PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs877144 611.1%   
Low Rs42479 536.1%   
Sales per share (Unadj.) Rs223.447.6 469.7%  
Earnings per share (Unadj.) Rs31.17.6 408.3%  
Cash flow per share (Unadj.) Rs40.39.0 447.0%  
Dividends per share (Unadj.) Rs5.002.25 222.2%  
Dividend yield (eoy) %0.82.0 38.0%  
Book value per share (Unadj.) Rs219.547.5 461.8%  
Shares outstanding (eoy) m33.07177.83 18.6%   
Bonus/Rights/Conversions PABB-  
Price / Sales ratio x2.92.3 124.4%   
Avg P/E ratio x20.914.6 143.2%  
P/CF ratio (eoy) x16.112.3 130.8%  
Price / Book Value ratio x3.02.3 126.6%  
Dividend payout %16.129.6 54.4%   
Avg Mkt Cap Rs m21,50419,784 108.7%   
No. of employees `000NANA-   
Total wages/salary Rs m1,1281,221 92.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m7,3898,459 87.4%  
Other income Rs m167394 42.5%   
Total revenues Rs m7,5568,852 85.4%   
Gross profit Rs m1,7932,070 86.6%  
Depreciation Rs m304249 122.2%   
Interest Rs m36631 1,180.9%   
Profit before tax Rs m1,2902,184 59.1%   
Minority Interest Rs m460-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309606 51.0%   
Profit after tax Rs m1,0271,353 75.9%  
Gross profit margin %24.324.5 99.2%  
Effective tax rate %23.927.7 86.3%   
Net profit margin %13.916.0 86.9%  
BALANCE SHEET DATA
Current assets Rs m3,6814,355 84.5%   
Current liabilities Rs m3,1231,792 174.3%   
Net working cap to sales %7.630.3 24.9%  
Current ratio x1.22.4 48.5%  
Inventory Days Days8944 201.3%  
Debtors Days Days5925 237.9%  
Net fixed assets Rs m7,6853,025 254.1%   
Share capital Rs m331179 185.2%   
"Free" reserves Rs m6,6708,243 80.9%   
Net worth Rs m7,2598,453 85.9%   
Long term debt Rs m95511 8,924.3%   
Total assets Rs m11,95710,557 113.3%  
Interest coverage x4.571.4 6.3%   
Debt to equity ratio x0.10 10,392.5%  
Sales to assets ratio x0.60.8 77.1%   
Return on assets %11.713.1 88.9%  
Return on equity %14.216.0 88.4%  
Return on capital %20.723.5 88.2%  
Exports to sales %39.413.3 295.7%   
Imports to sales %5.73.3 170.5%   
Exports (fob) Rs m2,9081,126 258.3%   
Imports (cif) Rs m421283 148.9%   
Fx inflow Rs m3,4451,146 300.6%   
Fx outflow Rs m703355 197.8%   
Net fx Rs m2,743791 346.8%   
CASH FLOW
From Operations Rs m1,4401,485 97.0%  
From Investments Rs m-1,089-620 175.8%  
From Financial Activity Rs m-353-753 46.9%  
Net Cashflow Rs m-1113 -1.3%  

Share Holding

Indian Promoters % 52.0 68.9 75.5%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 4.7 166.8%  
FIIs % 16.6 7.5 221.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 19.0 136.8%  
Shareholders   25,395 23,730 107.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SUN PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  DR. REDDYS LAB  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Sensex Touching New Highs, Takeaways from Acquisition of HPCL and Top Stocks in Action Today(Pre-Open)

BSE Sensex is on a roll. The index touched a record high of 35,798 yesterday. Considering a span of one year, the benchmark index has delivered a 32% return.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jan 22, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS